Principal Financial Group Inc. Has $737,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Principal Financial Group Inc. lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 5.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 88,622 shares of the company’s stock after selling 4,944 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $737,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMRX. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals in the second quarter valued at $26,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $42,000. nVerses Capital LLC acquired a new position in Amneal Pharmaceuticals during the 2nd quarter valued at about $62,000. Xponance Inc. bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $65,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter worth approximately $65,000. Institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the topic of several analyst reports. StockNews.com raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Piper Sandler upped their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Friday, September 6th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, Truist Financial boosted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Stock Up 0.8 %

AMRX opened at $8.39 on Friday. Amneal Pharmaceuticals, Inc. has a twelve month low of $4.16 and a twelve month high of $9.48. The company’s 50-day moving average price is $8.57 and its two-hundred day moving average price is $7.73. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -12.34 and a beta of 1.17.

Insider Buying and Selling

In related news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.